CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract.Cancer management and research · 2025
   Article
2. Stereotactic Body Radiation Therapy in Gynecologic Oligometastases: An Effective but Underutilized Approach.Cancers · 2023
   Review
3. A Decade-long Battle: Successful Stereotactic Radiotherapy for a Delayed Lung Metastasis from Endometrial Cancer.Gynecology and minimally invasive therapy
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

7 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as